Introduction {#s0005}
============

Cardiovascular disease (CVD) is the most important and leading cause of death in those with end-stage renal disease (ESRD) [@bib1], [@bib2]. In the general population, insulin resistance is related to several risk factors for CVD, including hypertension, dyslipidemia, diabetes, and central obesity [@bib3]. Furthermore, hyperinsulinemia itself and related-insulin resistance are directly associated with development of CVD [@bib4], [@bib5].

In patients with ESRD, many factors including uremia, chronic inflammation, and abnormal adipokines are involved in the development of insulin resistance. Previous studies revealed that insulin resistance was prevalent and was an independent predictor of cardiovascular mortality in nondiabetic patients with ESRD and on hemodialysis (HD) [@bib6]. In particular, in patients on peritoneal dialysis (PD), chronic exposure to high glucose-containing PD solution causes several hazard events including hypertriglyceridemia, poor glycemic control, new-onset diabetes, and central obesity [@bib7]. It is likely that these abnormalities aggravate insulin resistance in patients on PD [@bib7]. Furthermore, a recent study also showed a relationship between insulin resistance, as assessed by homeostatic model assessment of insulin resistance (HOMA-IR), and CVD in patients on PD [@bib8], [@bib9], [@bib10]. However, due to the relatively small sample size and the very low incidence rate of CVD seen in a previous study, earlier results would benefit from validation of the predictive role of insulin resistance in a larger population. Therefore, we investigated whether insulin resistance determined by HOMA-IR was an independent predictor of cardiovascular outcome in nondiabetic patients with ESRD and on PD.

Methods {#s0010}
=======

Ethics statement {#s0015}
----------------

The study was carried out in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Yonsei University Health System (YUHS) Clinical Trial Center, Seoul, Korea. We obtained informed written consent from all participants involved in the current study.

Patients {#s0020}
--------

All consecutive nondiabetic patients with ESRD older than 18 years of age who underwent PD for\>3 months at YUHS were initially screened for enrollment between January 2009 and December 2009 in this prospective observational study. Patients were considered eligible if they had no history of malignancy or chronic inflammatory disease such as systemic lupus erythematosus or rheumatoid arthritis, and had no overt infection during the 3 months prior to study entry. We also excluded patients with a history of kidney transplantation, a history of HD for\>3 months prior to PD, or a history of CVD within 3 months prior to study entry ([Fig. 1](#f0005){ref-type="fig"}).

Clinical and biochemical data collection {#s0025}
----------------------------------------

Demographic and clinical data recorded at study entry included: age, sex, PD duration, primary renal disease, smoking status, and medication use. Body mass index (BMI) and biochemical data were measured at study enrollment. Patients were weighed in light clothing, and height was measured with shoes off. BMI was calculated as weight/height (kg/m^2^). Diabetes mellitus was defined as previously described [@bib11]. Blood was taken after a 12-hour overnight fast, and the following laboratory data were measured: hemoglobin, glucose, blood urea nitrogen, creatinine, albumin, iron profile, triglyceride (TG), total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), calcium, phosphorus, and intact parathyroid hormone (iPTH) concentrations. Insulin resistance was assessed using the HOMA-IR equation as follows:$${HOMA} - {IR} = ({fasting}{insulin}{in}{microunits}{per}{liter} \times {fasting}{plasma}{glucose}{in}{mmol}/L/22.5)$$

In addition, high-sensitivity C-reactive protein (hs-CRP) concentrations were determined by a latex-enhanced immunonephelometric method using a BNII analyzer (Dade Behring, Newark, DE, USA). Kt/V urea was determined from the total loss of urea nitrogen in spent dialysate using PD Adequest 2.0 for Windows software (Baxter Healthcare, Deerfield, IL, USA).

Follow-up and end points {#s0030}
------------------------

Patients were followed up at 3-month intervals through January 1, 2014. All deaths and hospitalizations were noted in a serious adverse event database. All events were retrieved from the database and carefully reviewed to determine incident CVD. Primary outcomes were major cardiovascular events, which were defined as death or hospitalization from an acute coronary syndrome and stable angina requiring coronary revascularization or coronary artery bypass surgery. Cerebrovascular events were defined as transient ischemic attack, stroke, or carotid endarterectomy and peripheral vascular disease defined as ischemic limb loss and/or ulceration or peripheral revascularization procedure that also included major cardiovascular events. When a patient died within 60 days after transfer to HD, the death was regarded as a mortality event. Loss to follow-up, kidney transplantation, and transfer to HD were censored in the final analysis.

Statistical analysis {#s0035}
--------------------

Continuous variables were expressed as mean±standard deviation, or median (interquartile range), whereas categorical variables were expressed as a number (percentage). Normality of distribution was ascertained by the Kolmogorov-Smirnov test. Patients were divided into three groups according to the tertile value of their HOMA-IR. To compare the baseline characteristics, analysis of variance or Kruskal-Wallis test and Chi-square tests were used for continuous variables and categorical variables, respectively. Univariate and multivariate linear regression analyses were performed to determine significant factors associated with HOMA-IR. Comparisons for major cardiovascular events were performed by the Kaplan-Meier analysis and a log-rank test. The independent predictive value of HOMA-IR for primary outcome was confirmed by Cox proportional hazards regression models, which included significant variables in univariate analysis. Statistical analysis was performed with SPSS for Windows version 18.0 (SPSS Inc., Chicago, IL, USA). A *P* value\<0.05 was considered significant.

Results {#s0040}
=======

Demographic characteristics of patients {#s0045}
---------------------------------------

Baseline demographic and laboratory characteristics of patients are detailed in [Table 1](#t0005){ref-type="table"}. The mean age was 53.1±8.3 years and 99 patients (49.3%) were male. The mean value of HOMA-IR was 2.6±2.1. Patients were divided into three groups according to the tertile values of HOMA-IR. The three groups showed no significant differences in age, sex, previous history of CVD, proportion of smokers, dialysis adequacy, icodextrin user, total cholesterol, low-density lipoprotein cholesterol, log hs-CRP, or medication including renin-angiotensin-aldosterone system blockers or statin. However, BMI, impaired fasting glucose, and TG were significantly higher in the group with high HOMA-IR compared to the middle and low HOMA-IR groups (*P*=0.002, *P*=0.001, and *P*\<0.001, respectively). Meanwhile, HDL-C was significantly lower in the high HOMA-IR group (*P*=0.041).

Association between HOMA-IR and clinical and biochemical parameters {#s0050}
-------------------------------------------------------------------

In univariate analysis, HOMA-IR was positively associated with BMI, previous history of CVD, TG, and serum calcium level, but it was negatively associated with HDL-C ([Table 2](#t0010){ref-type="table"}). Multivariate linear regression analysis revealed that BMI, previous CVD, and TG had independent associations with HOMA-IR in patients on PD ([Table 3](#t0015){ref-type="table"}).

HOMA-IR as an independent predictor of major cardiovascular events {#s0055}
------------------------------------------------------------------

During a mean follow-up duration of 36.8±16.2 months, the primary outcome was observed in 36 patients (17.9%), and 12 patients (6.0%) died from a new-onset cardiovascular event. The patients with cardiovascular events were significantly older and had a much more prevalent history of previous CVD. The log hs-CRP and HOMA-IR were significantly higher, whereas % lean body mass (%LBM) was significantly lower in patients with new-onset cardiovascular events ([Table 4](#t0020){ref-type="table"}). A Kaplan-Meier plot showed that CVD event-free survival rates were significantly lower in the highest HOMA-IR tertile group than in the lower two HOMA-IR groups (log-rank test; *P*=0.029; [Fig. 2](#f0010){ref-type="fig"}). However, there was no difference in CVD event-free survival according to new onset diabetes (data not shown). In univariate Cox proportional hazard analysis, age, previous history of CVD, and log hs-CRP as well as HOMA-IR levels were significant risk factors for a primary outcome ([Table 5](#t0025){ref-type="table"}). In multivariate Cox analysis, HOMA-IR was a significant independent predictor of new-onset major cardiovascular events (hazard ratio: 1.18, 95% confidence interval: 1.03--1.35; *P*=0.014) after adjustment for age, sex, %LBM, previous CVD, and log hs-CRP ([Table 6](#t0030){ref-type="table"}).

Discussion {#s0060}
==========

In this observational study, we demonstrated that HOMA-IR was closely correlated with the parameters of metabolic syndrome such as BMI, impaired fasting glucose, and serum TG level. In addition, increased HOMA-IR was significantly associated with new-onset cardiovascular events as well as history of previous CVD. The current study showed that insulin resistance, as assessed by HOMA-IR, might be a risk factor for CVD in nondiabetic patients with prevalent PD.

Insulin resistance is a physiological circumstance in which cells are not able to react with normal responses to the hormonal effects of insulin. In the general population, several factors including obesity, increased TG level, sedentary lifestyle, and high-fat diet can induce insulin resistance [@bib12], [@bib13]. Adipose tissue in obese patients secreted proinflammatory cytokines and reduced insulin sensitivity [@bib14]. In addition, hyperleptinemia and decreased adiponectin levels induced impairment of insulin signaling [@bib15]. A previous study reported that high leptin and low adiponectin was prevalent and significantly associated with clinical outcomes in patients with prevalent PD [@bib16]. Decreased renal function is also associated with insulin resistance in nondialysis chronic kidney disease and ESRD patients. Kobayashi et al [@bib17] revealed that insulin resistance was linearly correlated with the decline of renal function in patients with chronic kidney disease. In addition to classic risk factors, chronic exposure to high-glucose-containing dialysate and its degradation products in patients with long-standing PD might exacerbate a series of metabolic influences such as dyslipidemia, hyperglycemia, visceral obesity, and subsequently cause increases in insulin resistance [@bib7], [@bib8], [@bib18]. Furthermore, impaired fasting glucose is associated with mortality in nondiabetic patients on PD [@bib19]. The current study also showed that HOMA-IR was significantly associated with components of metabolic syndrome, such as BMI, impaired fasting glucose, and serum TG level. Moreover, most of the study patients were anuric and were patients on prevalent PD of relatively long duration. Chronic exposure of high-glucose solution and the absence of residual renal might have aggravated insulin resistance in these study patients. Indeed, study patients have been maintained on PD with relatively long-standing duration, and we did not collect the exact data on high glucose containing dialysate including 2.5% or 4.25% solution. However, there were no significant differences in HOMA-IR according to use of non-glucose-based PD solution.

The connection between CVD and insulin resistance is well known, as they have been shown to be closely interrelated [@bib20], [@bib21], [@bib22]. Insulin resistance-related systemic inflammation and oxidative stress also frequently accompanies cardiovascular risk factors [@bib23], [@bib24]. The combined effect of insulin resistance and coexisting metabolic abnormality enhanced risks of cardiovascular events. In the current study, we confirmed that insulin resistance was principally associated with BMI and serum TG level as well as previous CVD. These markers are basically associated with metabolic disarrangement, or so-called "metabolic syndrome", and thus, insulin resistance is considered to be part of a "metabolic syndrome". Especially in patients with ESRD, metabolic disarrangement is more prominent and causes more severe adverse events such as cardiovascular disorder [@bib25]. Our study showed that HOMA-IR remained a significant variable even after adjustment for confounding variables, including hs-CRP. Based on this analysis, insulin resistance is associated with CVD, independent of systemic inflammation in patients on PD.

Chronic inflammation and protein-energy wasting play an important role in the development of CVD in patients with ESRD. Inflammation and malnutrition complex are closely associated with atherosclerosis and poor clinical outcomes in dialysis patients [@bib26]. The paradoxical inverse association between mortality and nutritional status in dialysis patients is referred to as "reverse epidemiology" [@bib27]. However, recent studies demonstrated that not only malnutrition but also obesity is associated with increased mortality in dialysis patients undergoing PD [@bib28]. Another study also reported that obesity including visceral adiposity is associated with insulin resistance and enhanced atherosclerosis in this population [@bib29]. Our study showed that insulin resistance is closely associated with BMI and new-onset cardiovascular events. Taken together with previous and current results, metabolic derangements, such as insulin resistance in patients undergoing PD, are closely affected atherosclerotic complications.

Malnutrition-inflammation complex syndrome is a nontraditional risk factor for CVD in ESRD. Serum albumin and %LMB is a classic marker for malnutrition and is a strong risk factor of mortality in dialysis patients [@bib30], [@bib31], [@bib32]. We evaluated the clinical significance of serum albumin and %LBM for new-onset cardiovascular events. The significance of these parameters was marginally valuable, although %LBM was a significant risk factor for CVD on univariate analysis. We had already excluded patients with chronic inflammatory status and active infection episodes and enrolled only relatively stable patients undergoing PD. Moreover, serum albumin is associated not only with inflammation but also fluid status and peritoneal transport status [@bib33]. Based on the results of the current study, insulin resistance, rather than malnutrition, was the primary contributor to the higher incidence of cardiovascular events in relatively well-nourished patients on PD.

There are several limitations to this study. First, the study patients were all Korean and undergoing prevalent PD at a single center, and the duration of PD in the study population was relatively diverse. Thus, selection bias is possible and there could be some limitation in the euglycemic clamp for practical reasons. Even though the accuracy of the euglycemic clamp is superior to other methods, its invasiveness may cause it to be difficult to use for a large study population. The HOMA-IR method is easy to use and results from HOMA-IR are usually consistent with results acquired by the euglycemic clamp technique [@bib34], [@bib35]. Finally, the absence of sequential follow-up measurements of HOMA-IR was another limitation in this study. A patient\`s insulin resistance might have changed during the follow-up period and time-averaged levels are much more reliable. Although we did not check HOMA-IR serially, however, we did enroll only patients on PD who were relatively stable. In the future, measurement of serial changes in insulin resistance would be helpful to improve the quality of significance in predicting prognosis.
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![**A flow diagram of the study.** All patients with ESRD older than 18 years of age who underwent PD for\>3 months were initially screened for enrollment between January 2009 and December 2009. Excluding 86 patients, a total of 201 patients were enrolled. HD, hemodialysis; SLE, systemic lupus erythematosus.](gr1){#f0005}

![**Kaplan-Meier plots for cardiovascular (CV) disease event-free survival between the lower two tertiles and the highest tertile group, according to the homeostatic model assessment of insulin resistance (HOMA-IR)**.](gr2){#f0010}

###### 

Baseline characteristics of patients according to the homeostatic model assessment of insulin resistance tertiles

  Variables                                         All (*n*=201)         1^st^ tertile (*n*=67)   2^nd^ tertile (*n*=67)   3^rd^ tertile (*n*=67)   *P*
  ------------------------------------------------- --------------------- ------------------------ ------------------------ ------------------------ ----------
  Age (y)                                           53.1±8.3              52.2±8.8                 52.3±8.0                 54.6±7.9                 0.16
  Male                                              99 (49.3)             34 (50.8)                35 (52.2)                30 (44.8)                0.67
  BMI (kg/m^2^)                                     23.4±3.0              22.6±2.3                 23.3±3.0                 24.4±3.5                 0.002
  \% Lean body mass                                 72.5±10.3             73.1±10.7                72.6±10.3                71.7±9.9                 0.74
  PD duration (mo)                                  83±54.3               96.3±54.5                71.2±48.3                81.5±57.6                0.027
  Kt/V                                              2.0±0.4               2.0±0.5                  2.0±0.4                  2.0±0.3                  0.93
  Icodextrin use                                    90 (44.8)             31 (46.3)                30 (44.8)                29 (43.3)                0.94
  Previous CVD[\*](#tbl1fn1){ref-type="table-fn"}   34 (16.9)             8 (4.0)                  12 (6.0)                 14 (7.0)                 0.37
  IFG                                               32 (15.9)             4 (6.0)                  9 (13.4)                 19 (28.4)                0.001
  New-onset DM                                      12 (6.0)              3 (1.5)                  3 (1.5)                  6 (3.0)                  0.28
  Smoker                                            49 (24.4)             16 (8.0)                 20 (10.0)                13 (6.5)                 0.37
  Hemoglobin (g/dL)                                 10.5±1.5              10.3±1.6                 10.8±1.6                 10.6±1.3                 0.12
  BUN (mg/dL)                                       60.7±19.0             61.6±19.0                62.4±19.4                58.2±18.5                0.39
  Creatinine (mg/dL)                                11.9±3.4              12.4±3.7                 11.6±3.4                 11.7±3.2                 0.35
  Albumin (g/dL)                                    3.6±0.4               3.5±0.4                  3.7±0.4                  3.7±0.5                  0.017
  Total cholesterol (mg/dL)                         182.1±36.1            176.8±36.9               183.8±37.2               185.8±34.1               0.32
  Triglyceride (mg/dL)                              140.6±106.8           100.3±52.1               137.2±80.1               184.2±147.9              \< 0.001
  HDL-C (mg/dL)                                     46.8±13.5             47.9±13.0                49.0±14.1                43.5±12.9                0.041
  LDL-C (mg/dL)                                     108.5±31.9            103.8±29.2               111.5±34.5               110.1±31.7               0.34
  Calcium (mg/dL)                                   9.0±0.8               8.9±0.7                  9.0±0.7                  9.1±1.0                  0.41
  Phosphate (mg/dL)                                 4.8±1.1               4.8±1.2                  4.8±1.2                  5.0±1.0                  0.85
  iPTH (pg/mL) (IQR)                                262.5 (71.5--322.8)   254 (80.6--343.0)        281.3 (71.0--212.7)      252 (41.0--313.0)        0.91
  log hs-CRP (mg/L)                                 0.2±0.8               0.2±0.8                  0.2±0.7                  0.3±0.8                  0.67
  Fasting glucose (mg/dL)                           91.7±15.3             86.8±10.2                91.1±9.1                 97.1±21.6                \< 0.001
  Fasting insulin (µU/mL)                           11.1±8.5              4.4±1.2                  9.2±2.0                  19.7±9.4                 \< 0.001
  HOMA-IR                                           2.6±2.1               0.9±0.3                  2.1±0.4                  4.7±2.2                  \< 0.001
  Medication                                                                                                                                         
   ACEi or ARB                                      178 (88.6)            62 (92.5)                58 (86.6)                58 (86.6)                0.46
   Ca-based P-binder                                163 (81.1)            56 (83.6)                53 (79.1)                53 (79.1)                0.42
   Non Ca-based P-binder                            40 (19.9)             13 (19.4)                12 (17.9)                15 (22.4)                0.34
   Statin                                           25 (12.4)             7 (10.5)                 7 (10.5)                 11 (16.4)                0.48

Data are presented as *n* (%) or mean±SD, unless otherwise indicated.

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; Ca, calcium; CVD, cardiovascular disease; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; hs-CRP, high-sensitivity c-reactive protein; IFG, impaired fasting glucose; iPTH, intact parathyroid hormone; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; P, phosphorus; PD, peritoneal dialysis; SD, standard deviation.

Cerebrovascular disease, coronary artery disease, peripheral artery disease.

###### 

Univariate linear regression analysis for the association of homeostasis model assessment-insulin resistance with clinical and biochemical variables (*n*=201)

  Variables                         β        *P*
  --------------------------------- -------- ----------
  Age                               0.133    0.06
  Female                            0.041    0.57
  Body mass index                   0.222    0.002
  \% Lean body mass                 −0.068   0.34
  Peritoneal dialysis duration      0.029    0.68
  Kt/V                              −0.079   0.27
  Previous cardiovascular disease   0.151    0.032
  Smoker                            −0.059   0.41
  Hemoglobin                        0.034    0.63
  BUN                               −0.96    0.18
  Creatinine                        −0.009   0.90
  Albumin                           0.138    0.051
  Total cholesterol                 0.051    0.47
  Triglyceride                      0.421    \< 0.001
  HDL-C                             −0.16    0.023
  LDL-C                             −0.002   0.98
  Calcium                           0.179    0.011
  Phosphate                         −0.037   0.6
  Intact parathyroid hormone        −0.07    0.32
  log hs-CRP                        0.058    0.41

BUN, blood urea nitrogen; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol.

###### 

Multivariate linear regression analysis for the association of homeostasis model assessment-insulin resistance with clinical and biochemical variables (*n*=201)

  Variables                         β        *P*
  --------------------------------- -------- ----------
  Age                               0.055    0.41
  Female                            −0.037   0.58
  Body mass index                   0.169    0.011
  Previous cardiovascular disease   0.137    0.029
  Triglyceride                      0.331    \< 0.001
  HDL-C                             0.017    0.81
  Calcium                           0.121    0.07

HDL-C, high-density lipoprotein cholesterol.

###### 

Clinical characteristics of subjects according to new-onset cardiovascular event

  Variables                                         New-onset CV event   Without CV event      *P*
  ------------------------------------------------- -------------------- --------------------- ----------
  Age (y)                                           57.9±7.5             52.0±8.1              \< 0.001
  Male                                              16 (44.4)            83 (50.3)             0.52
  Body mass index (kg/m^2^)                         24±3.4               23.3±3.0              0.29
  \% Lean body mass                                 67.8±10.1            73.5±10.1             0.003
  Peritoneal dialysis duration (mo)                 87.7±52.1            81.9±54.9             0.56
  Kt/V                                              2.0±0.3              2.0±0.4               0.83
  Previous CVD[\*](#tbl4fn1){ref-type="table-fn"}   11 (30.6)            23 (13.9)             0.016
  New-onset DM                                      2 (1.0)              10 (5.0)              0.63
  Smoker                                            6 (16.7)             43 (26.1)             0.23
  Hemoglobin (g/dL)                                 10.4±1.5             10.6±1.5              0.42
  BUN (mg/dL)                                       56.4±17.0            61.7±19.3             0.13
  Creatinine (mg/dL)                                11.3±3.3             12.0±3.4              0.27
  Albumin (g/dL)                                    3.5±0.4              3.6±0.5               0.31
  Total cholesterol (mg/dL)                         181.0±36.1           182.4±36.2            0.84
  Triglyceride (mg/dL)                              136.4±78.7           141.5±112.2           0.8
  HDL-C (mg/dL)                                     44.4±12.5            47.3±13.6             0.25
  LDL-C (mg/dL)                                     113.6±28.5           107.3±32.6            0.29
  Calcium (mg/dL)                                   9.0±1.0              9.0±0.8               0.91
  Phosphate (mg/dL)                                 4.7±1.2              4.9±1.1               0.31
  iPTH (pg/mL)                                      173.9 (71.5--32.9)   153.5 (53.4--454.1)   0.57
  log hs-CRP (mg/L)                                 0.6±1.0              0.1±0.7               0.012
  HOMA-IR                                           3.3±2.4              2.4±1.9               0.044

Data are presented as *n* (%) or mean ± SD.

BUN, blood urea nitrogen; CVD, cardiovascular disease; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; hs-CRP, high-sensitivity c-reactive protein; iPTH, intact parathyroid hormone; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.

Cerebrovascular disease, coronary artery disease, peripheral artery disease.

###### 

Univariate Cox regression analysis for the association of new-onset cardiovascular events with clinical and biochemical variables (*n*=201)

  Variables                                 Hazard ratio (95% CI)   *P*
  ----------------------------------------- ----------------------- ----------
  Age (per 1 y)                             1.107 (1.059--1.158)    \< 0.001
  Female                                    0.963 (0.497--1.867)    0.91
  Body mass index (per 1 kg/m^2^)           1.094 (0.981--1.221)    0.11
  \% Lean body mass (per 1%)                0.953 (0.920--0.987)    0.008
  Peritoneal dialysis duration (per 1 mo)   1.003 (0.997--1.009)    0.32
  Kt/V (per 1)                              0.867 (0.332--2.261)    0.77
  Previous CVD                              2.118 (1.042--4.308)    0.038
  Smoker                                    0.656 (0.272--1.580)    0.35
  Hemoglobin (per 1 g/dL)                   0.875 (0.695--1.102)    0.26
  BUN (per 1 mg/dL)                         0.989 (0.969--1.009)    0.27
  Creatinine (per 1 mg/dL)                  0.964 (0.865--1.075)    0.51
  Albumin (per 1 g/dL)                      0.603 (0.275--1.326)    0.21
  Total cholesterol (per 1 mg/dL)           0.998 (0.989--1.007)    0.65
  Triglyceride (per 1 mg/dL)                0.999 (0.996--1.003)    0.66
  HDL-C (per 1 mg/dL)                       0.979 (0.953--1.006)    0.13
  LDL-C (per 1 mg/dL)                       1.002 (0.993--1.012)    0.62
  Calcium (per 1 mg/dL)                     1.005 (0.667--1.514)    0.98
  Phosphate (per 1 mg/dL)                   0.885 (0.675--1.161)    0.38
  iPTH (per 1 pg/mL)                        1.000 (0.999--1.001)    0.54
  log hs-CRP (per 1 mg/L)                   1.850 (1.320--2.593)    \< 0.001
  HOMA-IR (per 1)                           1.180 (1.045--1.332)    0.008

BUN, blood urea nitrogen; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; hs-CRP, high-sensitivity c-reactive protein; iPTH, intact parathyroid hormone; LDL-C, low-density lipoprotein cholesterol.

###### 

Multivariate Cox regression analysis for the association of new-onset cardiovascular events with clinical and biochemical variables (*n*=201)

  Variables                                         Hazard ratio (95% CI)   *P*
  ------------------------------------------------- ----------------------- -------
  Age (per 1 y)                                     1.092 (1.035--1.152)    0.001
  Female                                            0.685 (0.310--1.511)    0.35
  \% Lean body mass (per 1%)                        0.978 (0.931--1.027)    0.37
  Previous CVD[\*](#tbl6fn1){ref-type="table-fn"}   1.534 (0.690--3.410)    0.29
  log hs-CRP (per 1 mg/L)                           2.286 (0.907--2.127)    0.13
  HOMA-IR (per 1)                                   1.180 (1.034--1.348)    0.014

CI, confidence interval; CVD, cardiovascular disease; HOMA-IR, homeostasis model assessment-insulin resistance; hs-CRP, high-sensitivity c-reactive protein.

Cerebrovascular disease, coronary artery disease, peripheral artery disease.
